LncRNA GAS5 Interacts with MicroRNA-10b to Inhibit Cell Proliferation and Migration and Induces Apoptosis in Colorectal Cancer

Rui-qi Yang, Zhe-zhu Jin, San-ya Jiang, and Yong-jun Jin

Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, China

Correspondence should be addressed to Yong-jun Jin; jinyongjun666678@163.com

Received 16 November 2021; Accepted 20 December 2021; Published 22 January 2022

Academic Editor: Osamah Ibrahim Khalaf

Copyright © 2022 Rui-qi Yang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. The purpose of this study was to study the effects of the GAS5/microRNA-10b axis on proliferation, migration, and apoptosis of colorectal cancer (CRC).

Methods. The expression levels of GAS5 and miR-10b in CRC tissues and cells were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Wound healing experiment was used to detect the effects of GAS5 and miR-10b on the migration of CRC cells. The luciferase reporter gene experiment was used to verify miRNA targets. Immunohistochemical assay was used to detect the expression of proteins related to metastasis and apoptosis in tumor tissues.

Results. The expression of GAS5 was downregulated in CRC tissues and cell lines. The overexpression of GAS5 can inhibit cell proliferation and progression, induce apoptosis in vitro, and inhibit the growth of CRC tumor in vivo. In contrast, the expression of miR-10b, a downstream target of GAS5, was increased in CRC tissues and cells. Suppression of the miR-10b gene can inhibit proliferation and metastasis and cause apoptosis of CRC cells. In addition, luciferase reports show that GAS5 inhibits the progression of CRC cells by binding to miR-10b. Rescue experiments showed that overexpressed miR-10b could reverse GAS5-mediated antitumor effect on CRC cells in vivo and in vitro.

Conclusions. LncRNA GAS5 interacts with miR-10b to inhibit cell proliferation and migration and induces apoptosis in colorectal cancer. GAS5 and miR-10b could become potential therapeutic targets for CRC.

1. Introduction

Colorectal cancer (CRC) is one of the most frequently diagnosed malignant tumors in the world [1]. About 2/3 of CRC patients come from developed countries [2]. Although some genetic factors, weight, physical activity, and smoking are associated with the prognosis of patients with CRC, many patients with CRC have recurrence and metastasis. Little is known about the detailed molecular mechanism of the occurrence and development of CRC.

Long noncoding RNA (LncRNA) is noncoding RNAs with a length of more than 200 nucleotides [3]. Some LncRNAs with a size of more than 90 kb are also known as microRNAs (miRNAs). The standard “non-coding” refers to the absence of open reading frames and/or conserved codons in transcripts. The ability to encode peptides is not necessarily in conflict with the knowledge of transcripts to act as functional RNAs. In fact, there is growing evidence that bifunctional transcripts can act as both protein templates and LncRNAs [4]. More and more evidence show that LncRNAs are involved in all aspects of cell physiology and are very important for the occurrence, development, and metastasis of cancer [5]. LncRNA growth inhibition-specific gene 5 (GAS5) is located at 1q25 [6]. Several studies have shown that GAS5 is downregulated and plays a role as a tumor suppressor gene in breast cancer [7], ovarian cancer [8], hepatocellular carcinoma [9], and CRC [10]. Additionally, increasing evidence confirms that GAS5 binds to miRNAs [11]. MiRNAs are small endogenous noncoding RNA molecules (about 22 nt), which play an important role in gene expression and can promote translation inhibition or degradation [12]. Among several candidate miRNAs that regulate cell progression, a large amount of evidence has reported that the expression of microRNA-10b (miR-10b)
is related to tumor growth and spread in many cancers [13, 14]. Recently, it has been reported that miR-10b promotes the cell migration and invasion in CRC tumors by targeting HOXD10 [15]. Based on the above studies, we speculate that GAS5 can regulate CRC progression by binding miR-10b, which has not been explored in previous studies. Therefore, in present study, we investigated the possible functions and mechanisms of the GAS5/miR-10b axis in CRC progression through in vivo and in vitro experiments, which may provide new ideas for CRC metastasis and treatment.

2. Materials and Methods

2.1. Patients and Specimens. From September 2018 to October 2020, 50 cases of primary colon cancer tissues and adjacent normal tissues were obtained from Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine. All subjects signed the informed consent form. The research was approved by the ethics committee of Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine (2021-208).

2.2. Cell Culture. The human CRC cell lines SW480 and HCT116 were purchased from Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and were cultured in RPMI-1640 (Gibco, USA) with 10% fetal bovine serum (FBS, Gibco, USA). GAS5 overexpression vector (GAS5) and empty vector, miR-10b mimics (miR-10b) and mimic NC (NC), miR-10B inhibitor (miR-10b-inh), and inhibitor NC (NC-inh) were synthesized by GenePharma (Shanghai, China). Transfection was conducted with Lipofectamine 2000 (Thermo Fisher Scientific, Inc., USA) according to the protocol.

2.3. Cell Proliferation and Apoptosis. Cell Counting Kit-8 (CCK-8) was utilized to detect the proliferative ability of
Figure 2: Continued.
Figure 2: Continued.
cells. The cells were planted into 96-plates with 10000 cells per well. The apoptosis rate was observed by Annexin V-FITC/PI apoptosis detection kit. Finally, the apoptosis rate was detected by flow cytometry.

2.4. Cell Migration Assay. Cells were added into 6-well plates and cultured to 90% concentration. Make artificial wound with 200 μL pipette. In order to calculate cell mobility, appropriate time points such as 24 and 48 h after cell images were selected. Mobility (or percentage of wound healing) is the ratio of 48 h migration area (0 h–48 h scratch area) to 0 h area.

2.5. Quantitative Real-Time PCR (qRT-PCR). The total RNA was extracted by the TRIzol Reagent (Invitrogen). SYBR® Premix Ex TaqTM II (Takara Bio, Shiga, Japan) was used to reverse transcribe total RNA into cDNA under the instruction guide of the manufacturer. SYBR Green Mastermix (Takara Bio, Japan) with a Step One Plus Real-Time PCR system (Applied Biosystems) was used for amplification.

2.6. Double Luciferase Report Experiment. Each sample has three values: RLU1-firefly luciferase reaction intensity, RLU2-inner reference sea kidney luciferase reaction intensity, and ratio-RLU1/RLU2. Generally, the ratio value can be recorded, but RLU1 and RLU2 are the actual fluorescence intensity values, which can reflect the transfection efficiency of cells, and the ratio of reporter plasmid to internal reference can also be adjusted according to the actual fluorescence intensity.

2.7. Immunohistochemistry Analysis. The biopsy specimens boiled 30 min in hydrogen peroxide and sealed 40 min with goat serum. The primary antibody was incubated at 4°C in serum (1RU 100) overnight. All sections were stained with 2-aminobenzidine (2-aminobenzidine) and hematoxylin (hematoxylin) for 60 min with HRP binding protein second antibody culture.

2.8. In Vivo Assay. 16 female nude mice were subcutaneously injected into the flank of BALB/c-nu mice to develop the subcutaneous tumor bearing model. Tumor weight and tumor volume were measured every 2 days.

2.9. Statistical and Analytical Methods. The data are shown as mean ± standard deviation (SD). SPSS 22.0 was used for statistical analysis. t-test was utilized to analyze the difference between the two groups. The differences between the two groups were compared by single factor analysis of variance. p < 0.05 was considered to be statistically significant.

3. Results

3.1. The Expression of GAS5 in CRC Tissues and Cell Line. At first, the expression of GAS5 was detected in 50 surgical specimens by qRT-PCR. The expression level of GAS5 in cancer tissues was lower than that in normal tissues adjacent to cancer (p < 0.05, Figure 1(a)), and the expression level of GAS5 in CRC cell lines SW480 and HCT116 was significantly downregulated compared with that in normal colon epithelial cells NCM460 (p < 0.01, Figure 1(b)). Kaplan Meier (KM) curve results showed that patients with low expression of GAS5 had poor prognosis (Figure 1(c)).

3.2. Overexpression of GAS5 Can Inhibit the Proliferation and Migration of CRC Cells. In order to elucidate the potential effect of GAS5 on CRC cells, 48 h after transfection of SW480 and HCT116 with GAS5 or vector, high expression of GAS5 (Figures 2(a) and 2(b)) was observed in the two
kinds of cells. CCK-8 assay was used to detect cell proliferation. The results showed that overexpression of GAS5 inhibited the proliferation of CRC cells. In addition, flow cytometry showed that the overexpression of GAS5 could induce apoptosis (Figure 2(c)) of SW480 and HCT116 cells. The results of the scratch test showed that the cell migration ability of SW480 and HCT116 was significantly inhibited (Figures 2(d) and 2(e)) after the overexpression of GAS5. In addition, we used qRT-PCR to detect the expression of apoptosis-related gene and EMT-related gene in CRC cells after the overexpression of GAS5. It was found that pro-apoptotic genes such as BAK and BAX were highly expressed after the overexpression of GAS5. On the contrary, antiapoptosis-related genes Bcl-2 showed low expression.

At the same time, the genes related to cell migration were also significantly downregulated after the overexpression of GAS5 (Figure 2(f)). These results suggest that the overexpression of GAS5 inhibits the proliferation and migration of CRC cells in vitro.

3.3. LncRNA GAS5 Targeting miR-10b in SW480 and HCT116 Cells. We used Starbase database (https://starbase.sysu.edu.cn/starbase2/index.php) to calculate the binding sites of GAS5 and miR-10b, and miR-10b was forecasted to bind with GAS5 directly in SW480 and HCT116 cells (Figure 3(a)). QRT-PCR showed that the expression of miR-10b was downregulated after the overexpression of GAS5; on the contrary, si-GAS5 transfection remarkably
Figure 4: Continued.
Cell viability (OD = 450NM)

HCT116

SW480

Control
MIR 10B inhibitor-NC
MIR10B inhibitor

Figure 4: Continued.
Figure 4: Continued.
enhances miR-10b level in SW480 and HCT116 cells (Figure 3(b)). The subsequent double luciferase report test further confirmed the direct binding of GAS5 and miR-10b (Figure 3(c)–3(d)).

3.4. miR-10b Promotes the Proliferation and Migration of CRC. The expression of miR-10b was detected, the results showed that the expression level of miR-10b in tumor tissues was significantly higher than that in normal tissues, and the same result was observed in cell lines (Figures 4(a) and 4(b)). In order to accurately study the function of miR-10b, we use miR-10b inhibitor (miR-10b-inh) to specifically inhibit miR-10b. Figure 4(c) shows the inhibition efficiency. CCK-8 assay was used to detect cell proliferation, and the results showed that miR-10b-inh inhibited the proliferation of CRC cells (Figure 4(d)). Flow cytometry showed that miR-10b-inh significantly increased the apoptosis ratio (Figures 4(e) and 4(f)) of CRC cell lines SW480 and HCT116. Wound healing test showed that miR-10b-inh inhibited the migration ability of SW480 and HCT116 cells (Figures 4(g) and 4(h)). The results suggest that miR-10b plays the role of oncogenes and maintains cell survival and metastasis.

3.5. Overexpressed miR-10b Reverses Antitumor Effects of LncRNA GAS5 in SW480 and HCT116 Cells. Next, we further verified that the interaction between GAS5 and miR-10b regulates the proliferation and migration of tumor cells in vitro. First of all, we constructed an overexpressed cell line and verified the transfection efficiency by qRT-PCR (Figure 5(a)). MiR-10b significantly restored GAS5-reduced cell proliferation in SW480 and HCT116 cells (Figure 5(b)). And miR-10b significantly reverses GAS5-induced cell apoptosis in SW480 and HCT116 cells (Figures 5(c) and 5(d)). In addition, miR-10b reversed GAS5-induced cell migration (Figures 5(e) and 5(f)). MiR-10b inhibited GAS5-reduced metastasis and proliferation-related mRNA expression and apoptosis-related mRNA expression (Figure 5(g)).

3.6. Overexpressed miR-10b Reverses Antitumor Effects of LncRNA GAS5 In Vivo. HCT116 cells were cotransfected with GAS5 or vector and miR-10b or miR-NC. As shown in Figure 6(a), tumor growth in the GAS5 group was markedly slower than that in the vector group. However, the overexpression of miR-10b restored tumor growth (Figure 6(a)).
**Figure 5: Continued.**

(a) Graph showing relative miR10B expression in SW480 and HCT116 cells with different treatments.

(b) Graph showing cell viability (OD = 450 nm) over time for SW480 and HCT116 cells with different treatments.

(c) Flow cytometry data showing annexin V-FITC and PI staining for apoptotic cells in SW480 and HCT116 cells with different treatments.

(d) Bar graph showing the percentage of apoptotic cells for SW480 and HCT116 cells with different treatments.
Figure 5: Continued.
Similarly, the tumor growth curve and tumor weight showed the same trend (Figures 6(b) and 6(c)). We measured the levels of ki67, BAK, Bcl-2, and E-cadherin in the tumor tissue. Compared with the vector group, the GAS5 group had downregulated ki67 and Bcl-2 expression and upregulated BAK and E-cadherin expression. On the contrary, miR-10b reversed the effect of GAS5 (Figure 6(d)). MiR-10b could obviously reverse antitumor effect of GAS5; thus, the GAS5 inhibits CRC tumorigenicity by suppressing miR-10b.

4. Discussion

LncRNA is a new star in the field of cancer diagnosis and treatment. Emerging evidence shows that the abnormal expression and mutation of IncRNA and SNPs are related to tumor occurrence and metastasis, affecting cancer cell proliferation, apoptosis, and EMT [16, 17]. More and more studies have reported significant changes in the expression of IncRNA in various cancer tissues, but the role of IncRNA is still controversial. Some IncRNAs play the role of promoting cancer in CRC, while others play the role of tumor suppressor. GAS5 was originally described by a potential tumor suppressor screening report with increased expression levels during growth arrest [18]. Previous studies have explored the role of GAS5 in cancer [19]. Previous reports have shown that GAS5 is underexpressed in various cancers and acts as a tumor suppressor, including CRC [20], osteosarcoma [21], and lung cancer [22]. This study revealed that GAS5 was significantly downregulated in CRC tissues and cells. Functional experiments showed that the overexpression of GAS5 could inhibit migration and proliferation of CRC cells in vitro and inhibit the occurrence of CRC tumor in vivo. We proved that GAS5 functioned as a tumor suppressor in CRC.

It is reported that GAS5 can combine various miRNAs in some common cancers. GAS5 inhibits the proliferation of gliomas by regulating PTEN through microRNA-106b [23]. LncRNAGAS5 inhibits the invasion and proliferation.
Figure 6: Overexpressed miR-10b reverses antitumor effects of LncRNA GAS5 in vivo. (a) Represented images of tumors. (b) Tumor volumes. (c) Represented tumor weights. (d) Represented the levels of ki67, BAK, Bcl-2, and E-cadherin in the tumor tissue. *$p < 0.5$, **$p < 0.01$, ***$p < 0.001$. Data represent at least three independent sets of experiment.
of ovarian clear cell carcinoma through the miR-31-5p/ARID1A axis [24]. At the same time, other studies have shown that LncRNA GAS5 inhibits the activation of SIRT1/PGC-1α/Nrf2 signal pathway by miR-579-3p and reduces cell death in septicemia-related renal injury [25]. It is well known that the role of cell death in antitumor has become more and more obvious.

A great deal of evidence has reported that the miR-10b expression is related to tumor growth and spread in many cancers. Mir-10b plays an inhibitory role in the development of gastric cancer [26]. Zou et al. found that the downregulation of miR-10b in cervical cancer tissue and the resulting increase in HOXA1 levels may play a key role in the progression of cervical cancer [27]. Li et al. found that TUC338 may promote bladder cancer by upregulating miR-10b [28]. In this study, the expression of miR-10b in CRC tissues and cells was significantly increased and the downregulation of miR-10b inhibited the progress of CRC cells, which was consistent with previous studies. Subsequently, miR-10b is predicted to be the target of GAS5. Therefore, we further explore whether GAS5/miR-10b is related to the progress of CRC. The results show that overexpressed GAS5 plays an antitumor effect through direct interaction with miR-10b in vitro and in vivo.

5. Conclusion

In present study, we demonstrated that GAS5 was downregulated, and miR-10b was upregulated in CRC tissues and cell lines. The overexpression of GAS5 can inhibit cell proliferation and migration, promote apoptosis in vitro, and inhibit the growth of CRC tumor in vivo. Moreover, GAS5 exhibited antitumor effects via direct interaction with miR-10b. The regulatory network of the GAS5/miR-10b axis may provide new ideas for the metastasis and treatment of CRC.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Ethical Approval

This study was approved by the Medical Ethics Committee of Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine (2021-208).

Conflicts of Interest

The authors have declared that no competing interesting exists.

Acknowledgments

This work was supported by a grant from the Hangzhou Health Science and Technology Project (no. 2017A43).

References

[1] G. D. Leonard, B. Brenner, and N. E. Kemeny, “Neoadjuvant chemotherapy before liver resection for patients with unresectable liver metastases from colorectal carcinoma,” Journal of Clinical Oncology, vol. 23, no. 9, pp. 2038–2048, 2005.

[2] J. Cassidy, “Benefits and drawbacks of the use of oral fluoropyrimidines as single-agent therapy in advanced colorectal cancer,” Clinical Colorectal Cancer, vol. 5, Supplement 1, pp. S47–S50, 2005.

[3] G. J. Goodall and V. O. Wickramasinghe, “RNA in cancer,” Nature Reviews. Cancer, vol. 21, no. 1, pp. 22–36, 2021.

[4] X. Li, L. Hou, L. Yin, and S. Zhao, “LncRNA XIST interacts with miR-454 to inhibit cells proliferation, epithelial mesenchymal transition and induces apoptosis in triple-negative breast cancer,” Journal of Biosciences, vol. 45, no. 1, p. 45, 2020.

[5] S. Khan, M. Masood, H. Gaur, S. Ahmad, and M. A. Syed, “Long non-coding RNA: an immune cells perspective,” Life Sciences, vol. 271, article 119152, 2021.

[6] E. A. Toraih, S. A. Alghamdi, A. el-Wazir et al., “Dual biomarkers long non-coding RNA GAS5 and microRNA-34a co-expression signature in common solid tumors,” PLoS One, vol. 13, no. 10, article e0198231, 2018.

[7] S. Zheng, M. Li, K. Miao, and H. Xu, “IncrRNA GAS5- promoted apoptosis in triple-negative breast cancer by targeting miR-378a-5p/SUFU signaling,” Journal of Cellular Biochemistry, vol. 121, no. 3, pp. 2225–2235, 2020.

[8] J. Li, C. Yang, Y. Li, A. Chen, L. Li, and Z. You, “LncRNA GAS5 suppresses ovarian cancer by inducing inflammasome formation,” Bioscience Reports, vol. 38, no. 2, 2018.

[9] L. Hu, H. Ye, G. Huang et al., “Long noncoding RNA GAS5 suppresses the migration and invasion of hepatocellular carcinoma cells via miR-21,” Tumour Biology, vol. 37, no. 2, pp. 2691–2702, 2016.

[10] K. Cheng, Z. Zhao, G. Wang, J. Wang, and W. Zhu, “IncrRNA GAS5 promotes invasion by targeting HOXD10 in colorectal cancer,” Oncology Reports, vol. 40, no. 4, pp. 2371–2380, 2018.

[11] L. Liu, H. J. Wang, T. Meng et al., “IncrRNA GAS5 inhibits colorectal cancer cell proliferation via the miR-182-5p/FOXO3a axis,” Oncology Reports, vol. 31, no. 5, pp. 239–249, 2005.

[12] N. Zhang, X. Hu, Y. Du, and J. Du, “The role of miRNAs in colorectal cancer progression and chemoradiotherapy,” Biomedicine & Pharmacotherapy, vol. 134, 2021.

[13] E. O’Day and A. Lal, “MicroRNAs and their target gene networks in breast cancer,” Breast Cancer Research, vol. 12, no. 2, p. 201, 2010.

[14] P. Sheedy and Z. Medarova, “The fundamental role of miR-10b in metastatic cancer,” American Journal of Cancer Research, vol. 8, no. 9, pp. 1674–1688, 2018.

[15] Y. Wang, Z. Li, X. Zhao, X. Zuo, and Z. Peng, “miR-10b promotes invasion by targeting HOXD10 in colorectal cancer,” Oncology Letters, vol. 12, no. 1, pp. 488–494, 2016.

[16] F. Kopp and J. T. Mendell, “Functional classification and experimental dissection of long noncoding RNAs,” Cell, vol. 172, no. 3, pp. 393–407, 2018.

[17] G. St Laurent, C. Wahlestedt, and P. Kapranov, “The landscape of long noncoding RNA classification,” Trends in Genetics, vol. 31, no. 5, pp. 239–251, 2015.
[18] W. Ni, S. Yao, Y. Zhou et al., "Long noncoding RNA GAS5 inhibits progression of colorectal cancer by interacting with and triggering YAP phosphorylation and degradation and is negatively regulated by the m6A reader YTHDF3," *Molecular Cancer*, vol. 18, no. 1, p. 143, 2019.

[19] D. Han, Y. Wang, Y. Wang et al., "The tumor-suppressive human circular RNA CircITCH sponges miR-330-5p to ameliorate doxorubicin-induced cardiotoxicity through upregulating SIRT6, survivin, and SERCA2a," *Circulation Research*, vol. 127, no. 4, pp. e108–e125, 2020.

[20] L. Liu, T. Meng, X. H. Yang et al., "Prognostic and predictive value of long non-coding RNA GAS5 and microRNA-221 in colorectal cancer and their effects on colorectal cancer cell proliferation, migration and invasion," *Cancer Biomarkers*, vol. 22, no. 2, pp. 283–299, 2018.

[21] J. Liu, M. Chen, L. Ma, X. Dang, and G. Du, "LncRNA GAS5 suppresses the proliferation and invasion of osteosarcoma cells via the miR-23a-3p/PTEN/PI3K/AKT pathway," *Cell Transplantation*, vol. 29, article 963689720953093, 2020.

[22] N. Zhang, G. Q. Yang, X. M. Shao, and L. Wei, "GAS5 modulated autophagy is a mechanism modulating cisplatin sensitivity in NSCLC cells," *European Review for Medical and Pharmacological Sciences*, vol. 20, no. 11, pp. 2271–2277, 2016.

[23] X. P. Zhu, S. A. Pan, Z. Chu, Y. X. Zhou, Y. K. Huang, and D. Q. Han, "LncRNA GAS5 regulates epithelial-mesenchymal transition and viability of glioma cells by targeting microRNA-106b and regulating PTEN expression," *Neuroscience Research*, vol. 170, pp. 32–40, 2021.

[24] J. Zhang, Z. M. Yang, Y. Huang, K. N. Wang, Y. Xie, and N. Yang, "LncRNA GAS5 inhibits the proliferation and invasion of ovarian clear cell carcinoma via the miR-31-5p/ARID1A axis," *The Kaohsiung Journal of Medical Sciences*, vol. 37, no. 11, pp. 940–950, 2021.

[25] H. Ling, Q. Li, Z. P. Duan, Y. J. Wang, B. Q. Hu, and X. G. Dai, "LncRNA GAS5 inhibits miR-579-3p to activate SIRT1/PGC-1alpha/Nrf2 signaling pathway to reduce cell pyroptosis in sepsis-associated renal injury," *American Journal of Physiology. Cell Physiology*, vol. 321, no. 1, pp. C117–C133, 2021.

[26] F. Liu, X. An, X. Zhao et al., "MiR-10b-5p inhibits tumorigenesis in gastric cancer xenograft mice model through down-regulating Tiam1," *Experimental Cell Research*, vol. 407, no. 2, 2021.

[27] D. Zou, Q. Zhou, D. Wang, L. Guan, L. Yuan, and S. Li, "The downregulation of microRNA-10b and its role in cervical cancer," *Oncology Research*, vol. 24, no. 2, pp. 99–108, 2016.

[28] G. Li, Y. Zhang, J. Mao et al., "LncRNA TUC338 is a potential diagnostic biomarker for bladder cancer," *Journal of Cellular Biochemistry*, vol. 120, no. 10, pp. 18014–18019, 2019.